Urokinase fibrinolysis

Description Results NMA

urokinase bolus dose of 1 million U repeated after 60 minutes plus heparin (n=1128)

vs.

control (heparin alone) (n=1073)

open

Parallel groups

Sample size: 1128/1073

Primary endpoint:

FU duration: in hospital

All cause death 0.82 [0.29; 2.32]

major bleeding 1.90 [0.99; 3.66]

minor bleeding 1.43 [0.68; 2.98]

recurrence of pulmonary embolism 0.76 [0.38; 1.52]

urokinase 2,000-U/lb bolus, then 2,000 U/lb per h IV for 12 h and heparin (n=82)

vs.

placebo + Heparin (a loading dose of 75 U/pound, then 10 U/pound/hr for 12 hr infusion, then heparin for a minimum of 5 days, followed by heparin or warfarin therapy for a total of 14 days) (n=78)

double blind

Parallel groups

Sample size: 82/78

Primary endpoint:

FU duration: <14 days

urokinase 800,000 U/d IV for 72 h, UK 3,300,000 U IV for 12 h and heparin (n=20)

vs.

heparin (n=10)

open

Sample size: 20/10

Primary endpoint:

FU duration: 7 days

Mortality (early) 0.00 [0.00; NaN]

Bleeding (early) 0.61 [0.18; 2.06]

Any improvement in venous patency (early) 0.73 [0.05; 9.97]

Stroke/intracerebral bleeding (eraly) NaN [NaN; NaN]

Complete clot lysis (late) 2.13 [1.17; 3.86]

Mortality (early) ∞ [NaN; ∞]

Post-thrombotic syndrome (late) 0.65 [0.40; 1.04]

Leg ulceration (late) 1.00 [0.07; 15.00]

Stroke/intracerebral bleeding (eraly) NaN [NaN; NaN]

urokinase 200,000 U IV over 24 hours. After 18 hours, heparin loading dose of 15,000 units then 40,000 U/day for 5 days (+placebo) (n=20)

vs.

heparin 40,000 U/day IV for 6 days (+placebo) (n=0)

Double blind

Parallel groups

Sample size: 20/0

Primary endpoint:

FU duration:

Urokinase 100,000 IU/hr IV into pedal vein continuously for 7 days. Heparin IV for 7 days. Plasminogen monitored. Warfarin from day 7 to 12 monthsd=132 (n=-9)

vs.

heparin IV, adjusted for 7 days (n=-9)

single blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration:

Local urokinase 100,000 IU/day infused continuously. Fibrinogen and plasminogen monitored. Heparin IV given concomitantly (n=-9)

vs.

heparin IV, adjusted (n=-9)

single blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration:

Systemic urokinase 5,000,000 IU/day over 4 hours for up to 7 days. IV heparin given concomitantly (n=-9)

vs.

heparin IV, adjusted (n=-9)

single blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: